辛伐他汀在裸鼠模型中对乳腺癌骨转移的影响

摘要/Abstract

摘要：目的观察辛伐他汀在裸鼠模型中对乳腺癌骨转移的作用。方法采用完全随机分组方法将60只裸鼠分为3组，每组20只，裸鼠左心腔注射乳腺癌骨转移细胞株（MDAMB231），7 d后，分别皮下注射辛伐他汀、生理盐水及无任何处理（2次/周，19 d）。应用图像分析软件评估骨转移瘤的面积。随后处死裸鼠，用放射免疫法检测骨转移癌髓腔内甲状旁腺素相关蛋白（PTHrP）浓度；应用骨密度检测软件进行组织形态学分析，计数骨转移灶每毫米癌组织与临近骨小梁之间破骨细胞的数量。计量资料比较采用方差分析，P＜0.05为差异有统计学意义。结果与生理盐水组和无处理组相比，注射辛伐他汀的裸鼠骨转移癌面积明显减小（0.51±0.18 mm2 vs 2.13±1.24 mm2 vs 2.29±1.22 mm2; F=15.600,P=0.002；F=15.673，P=0.001），骨转移癌周围髓腔内PTHrP浓度明显降低（0.98±0.20 pmol/L vs 2.11±0.31 pmol/L vs 1.99±0.29 pmol/L; F=61.469,P＜0.001；F=58.274，P＜0.001）,并且其转移灶破骨细胞的数量明显减少（4.00±1.73个/mm vs 11.40±4.93个/mm vs 10.91±3.87个/mm; F=17.820,P=0.001，F=17.184，P=0.002）。结论辛伐他汀能够降低乳腺癌细胞PTHrP的分泌，从而抑制乳腺癌细胞在骨内生长及其对骨质的破坏。

关键词:乳腺肿瘤,肿瘤转移,斯伐他汀,甲状旁腺素

Abstract:ObjectiveTo observe the effect of simvastatin on bone metastasis of breast cancer in nude mice model. MethodsSixty mice were divided into three groups randomly with 20 in each group. Mice were inoculated with MDAMB231 cells into the left cardiac ventricle. After 7 days, mice were treated with either simvastatin, saline, or nothing twice per week for 19 days. The area of osteolytic metastases was subsequently measured in long bones of all mice using an image analysis system. After sacrifice, parathyroid hormonerelated protein (PTHrP) concentrations in bone marrow from all mice were determined using a twosite immunoradiometric assay. Osteoclast number expressed per millimeter of tumor/bone interface was assessed using an OsteoMeasure System. Measured data were compared with analysis of variance, and P＜0.05 for the difference was statistically significant. ResultsThe area of osteolytic lesions was significantly lower in mice treated with simvastatin compared with mice receiving saline and no treatment (0.51±0.18 mm2 vs 2.13±1.24 mm2 vs 2.29±1.22 mm2; F=15.600, P=0.002; F=15.673, P=0.001). In addition, treatment with simvastatin decreased the concentrations of PTHrP in bone marrow plasma (0.98±0.20 pmol/L vs 2.11±0.31 pmol/L vs 1.99±0.29 pmol/L; F=61.469, P＜0.001; F=58.274, P＜0.001) and the osteoclast numbers per millimeter of tumor/bone interface (4.00±1.73 vs 11.40±4.93 vs 10.91±3.87; F=17.820, P=0.001; F=17.184, P=0.002) compared with controls. ConclusionSimvastatin may reduce the production of PTHrP of breast cancer cells, which suppresses the development of destructive bone lesions as well as the growth of breast cancer cells in bone.

Key words:Breast neoplasms,Neoplasm metastasis,Simvastatin,Parathyroid hormone

陈明霞, 张蔚, 曲建力, 李强, 王海. 辛伐他汀在裸鼠模型中对乳腺癌骨转移的影响[J]. 国际肿瘤学杂志, 2015, 42(1): 5-9.

Chen Mingxia, Zhang Wei, Qu Jianli, Li Qiang, Wang Hai. Effects ofsimvastatinon human breast cancer osteolytic bone metastasis in a nude mice model[J]. Journal of International Oncology, 2015, 42(1): 5-9.

参考文献

［1］ Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies［J］. Cancer Treat Rev, 2001, 27(3): 165-176. ［2］ Ahn KS, Sethi G, Chaturvedi MM, et al. Simvastatin, 3hydroxy3methylglutaryl coenzyme a reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factorkappaB ligand through modulation of NFkappaB pathway［J］. Int J Cancer, 2008, 123(8): 1733-1740. ［3］ Drabsch Y, ten Dijke P. TGFβ signaling in breast cancer cell invasion and bone metastasis［J］. J Mammary Gland Biol Neoplasia, 2011, 16(2): 97-108. ［4］ Oh K, Lee OY, Shon SY, et al. A mutual activation loop between breast cancer cells and myeloidderived suppressor cells facilitates spontaneous metastasis through IL-6 transsignaling in a murine model［J］. Breast Cancer Res, 2013, 15(5): R79. ［5］ Bolin C, Tawara K, Sutherland C, et al. Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation［J］. Genes Cancer, 2012, 3(2): 117-130. ［6］ ArtachoCordón F, RíosArrabal S, Lara PC, et al. Matrix metalloproteinases: potential therapy to prevent the development of second malignancies after breast radiotherapy［J］. Surg Oncol, 2012, 21(3): e143-151. ［7］ Eck SM, Hoopes PJ, Petrella BL, et al. Matrix metalloproteinase1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model［J］. Breast Cancer Res Treat, 2009, 116(1): 79-90. ［8］ Jin R, Sterling JA, Edwards JR, et al. Activation of NFkappa B signaling promotes growth of prostate cancer cells in bone［J］. PLoS One, 2013, 8(4): e60983. ［9］ Diel IJ. Bone metastasis in breast cancer［J］. Breast Care (Basel), 2012, 7(2): 90-91. ［10］ Ito T, Takemasa M, Makino K, et al. Preparation of calcium phosphate nanocapsules including simvastatin/deoxycholic acid assembly, and their therapeutic effect in osteoporosis model mice［J］. J Pharm Pharmacol, 2013, 65(4): 494-502. ［11］ Savopoulos Ch, Dokos Ch, Kaiafa G, et al. Adipogenesis and osteoblastogenesis: transdifferentiation in the pathophysiology of bone disorders［J］. Hippokratia, 2011, 15(1): 18-21. ［12］ Jakobisiak M, Golab J. Statins can modulate effectiveness of antitumor therapeutic modalities［J］. Med Res Rev, 2010, 30(1): 102-135. ［13］ Manu KA, Shanmugam MK, Li F, et al. Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factorkappa Bregulated gene products［J］. J Mol Med (Berl), 2014, 92(3): 267-276. ［14］ Fendrich V, Sparn M, Lauth M, et al. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer［J］. Pancreatology, 2013, 13(5): 502-507. ［15］ Yu X, Pan Y, Ma H, et al. Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells［J］. Oncol Res, 2013, 20(8): 351-357. ［16］ Fang Z, Tang Y, Fang J, et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway［J］. PLoS One, 2013, 8(5): e62823. ［17］ Park YH, Seo SY, Lee E, et al. Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor B pathway［J］. J Urol, 2013, 189(4): 1547-1552. ［18］ Goc A, Kochuparambil ST, AlHusein B, et al. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis［J］. BMC Cancer, 2012, 12: 409. ［19］ Lee J, Lee I, Han B, et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations［J］. J Natl Cancer Inst, 2011, 103(8): 674-688. ［20］ Relja B, Meder F, Wilhelm K, et al. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells［J］. Int J Med, 2010, 26(5): 735-741. ［21］ Park IH, Kim JY, Choi JY, et al. Simvastatin enhances irinotecaninduced apoptosis in human nonsmall cell lung cancer cells by inhibition of proteasome activity［J］. Investigational new drugs, 2011, 29(5): 883-890. ［22］ Hwang KE, Na KS, Park DS, et al. Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent downregulation of survivin［J］. Invest New Drugs, 2011, 29(5): 945-952. ［23］ Gopalan A, Yu W, Sanders BG, et al. Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway［J］. Cancer Lett, 2013, 329(1): 9-16. ［24］ Kang S, Kim ES, Moon A. Simvastatin and lovastatin inhibit breast cell invasion induced by HRas［J］. Oncol Rep, 2009, 21(5): 1317-1322. ［25］ Mandal CC, GhoshChoudhury N, Yoneda T, et al. Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44［J］. J Biol Chem, 2011, 286(13): 11314-11327. ［26］ Boyce BF, Yao Z, Xing L. Functions of nuclear factor kappaB in bone［J］. Ann NY Acad Sci, 2010, 1192: 367375. ［27］ GhoshChoudhury N, Mandal CC, GhoshChoudhury N, et al. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth［J］. Cell Signal, 2010, 22(5): 749-758.

[1]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[5]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[6]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[7]	顾花艳, 朱腾, 郭贵龙.乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[8]	王景, 许文婷.中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[9]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[10]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰.miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[11]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英.免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[12]	王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[13]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	杨丽蓉, 王羽丰.预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[15]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏.HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.